Belzutifan Combined with Pembrolizumab for Resected Renal Cell Carcinoma
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on July 20th, 2026
|
Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is an established adjuvant therapy for patients with high-risk renal cell carcinoma following nephrectomy. By blocking the PD-1 pathway, pembrolizumab restores antitumor immune activity and reduces the risk of disease recurrence. However, despite this treatment, approximately 40% of patients experience disease recurrence within five years of surgery. To further improve outcomes, a recent study evaluated the addition of belzutifan to adjuvant pembrolizumab therapy.
Publication: New England Journal of Medicine
Funding Source(s): Merck
The phase 3 clinical trial enrolled 1,841 participants with a median age of approximately 60 years who had undergone complete surgical resection of renal cell carcinoma. Around 10% of patients received a partial nephrectomy, while the remainder underwent radical nephrectomy. Histopathological analysis showed that 27% of tumors were grade 4, whereas approximately 35% were grade 3 and another 35% were grade 2. Participants were randomly assigned to receive either placebo or oral belzutifan at a daily dose of 120 mg. All patients also received intravenous pembrolizumab at a dose of 400 mg every six weeks.
Belzutifan is a hypoxia-inducible factor-2α (HIF-2α) inhibitor that suppresses tumor growth by blocking pathways involved in cellular adaptation to hypoxia, angiogenesis, and cancer cell proliferation. Combining belzutifan with pembrolizumab was hypothesized to provide complementary antitumor activity through both immune activation and inhibition of HIF-2α signaling.
After a median follow-up of 28.4 months, the researchers found that the addition of belzutifan reduced the risk of disease recurrence or death by 28% compared with pembrolizumab alone. However, treatment with belzutifan was associated with a higher incidence of adverse events, particularly anemia and elevated alanine aminotransferase levels. These findings suggest that combining HIF-2α inhibition with immune checkpoint blockade may further improve outcomes in patients with resected renal cell carcinoma, although careful monitoring for treatment-related toxicities remains important.
Publication: New England Journal of Medicine
Funding Source(s): Merck
The phase 3 clinical trial enrolled 1,841 participants with a median age of approximately 60 years who had undergone complete surgical resection of renal cell carcinoma. Around 10% of patients received a partial nephrectomy, while the remainder underwent radical nephrectomy. Histopathological analysis showed that 27% of tumors were grade 4, whereas approximately 35% were grade 3 and another 35% were grade 2. Participants were randomly assigned to receive either placebo or oral belzutifan at a daily dose of 120 mg. All patients also received intravenous pembrolizumab at a dose of 400 mg every six weeks.
Belzutifan is a hypoxia-inducible factor-2α (HIF-2α) inhibitor that suppresses tumor growth by blocking pathways involved in cellular adaptation to hypoxia, angiogenesis, and cancer cell proliferation. Combining belzutifan with pembrolizumab was hypothesized to provide complementary antitumor activity through both immune activation and inhibition of HIF-2α signaling.
After a median follow-up of 28.4 months, the researchers found that the addition of belzutifan reduced the risk of disease recurrence or death by 28% compared with pembrolizumab alone. However, treatment with belzutifan was associated with a higher incidence of adverse events, particularly anemia and elevated alanine aminotransferase levels. These findings suggest that combining HIF-2α inhibition with immune checkpoint blockade may further improve outcomes in patients with resected renal cell carcinoma, although careful monitoring for treatment-related toxicities remains important.